Candidates / 4919

Milbon Co.,Ltd.4919・Chemicals

Activist stake: Misaki Capital. Of the listed companies with this trait in 2021–22, 1 in 5 was bought in the following four years or so — against 1 in 11 for all listed companies.

Taking every trait together, its score is 1.8x the average — #503 of 3,751. The closest type of deal is private equity.

Score1.8xvs average; #503 of 3,751
Past, similar score1 in 5were bought (19%)
Closest typePE fund
Price-to-book2.13xmarket value ¥104.7bn

Why it looks like past targets

Score by type of buyer

Typevs average for the type
Buyout by the parent0.3x
Management buyout2.2x
Private equity4.7x
Strategic buyer1.8x

Ownership

Top 10 shareholders

HolderTypeStake
日本マスタートラスト信託銀行株式会社(信託口)Custodian/nominee9.7%
鴻池資産管理株式会社Founder's holding company8.8%
株式会社コーセーCompany4.2%
ミルボン従業員持株会Employee/partner plan2.3%
株式会社日本カストディ銀行(信託口)Custodian/nominee2.2%
RBC IST 15 PCT NON LENDING ACCOUNT-CLIENT ACCOUNTCustodian/nominee2.1%
STATE STREET BANK AND TRUST COMPANYCustodian/nominee1.9%
村井 佳比子Individual1.5%
北嶋 舞子Individual1.5%
大阪佐々木化学株式会社Company1.5%

From the annual report for the year to 2025-12-31. Holder types are assigned by name and can be wrong (for example, a founder’s company can look like an operating company). Annual report (PDF, EDINET)

Key figures

Controlling shareholder (over 50%)
No
Largest corporate holder
4.2%
Founder family (individuals and their companies)
11.8%
Officers
0.3%
Net cash ÷ market value
12%
ROE
7.0%
Equity ratio
85%

Activist filings

Estimated cost = total acquisition funds ÷ shares held, from the latest report (or the previous one if the latest does not state the funds). Trades after the report's base date are not included. Stakes whose reports give no funding figure are left out. Share splits after the report are adjusted using the change in shares outstanding. Costs outside the stock's price range while held (0.8x the monthly low to 1.2x the high) are treated as reporting quirks (e.g. funds not updated after selling) and not shown. Stakes cut below 5% (mostly sold) are left out of the totals.

This site ranks listed companies by how closely their public filings (annual reports and large-shareholding reports) resemble past tender-offer and MBO targets. It is not a prediction that any company will be bought, is not based on any non-public information, and is not a recommendation to buy or sell. Not investment advice.

Updated 29 Sep 2026 00:48 JST